Keywords: high-dose chemotherapy; non-Hodgkin's lymphoma; autologous stem cells The outcomes for patients with non-Hodgkin's lymphoma (NHL) treated with high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) infusion by practicing oncologists in community cancer centers
Patients and methods
criteria of ASCO/ASH guidelines for stem cell transplantation. 31 As experience was acquired, patients remained in the outpatient department and were admitted only for comPatient selection plications such as fever and poor oral intake. Between February 1990 and July 1994, 83 patients with intermediate, high-grade or transformed NHL failing to achieve a complete remission (CR) with initial induction Mobilization of PBSC chemotherapy or relapsing following an initial remission were enrolled on one of two consecutive protocols. The
Patients had PBSC collected following the administration initial protocol was a phase II trial of high-dose BEAC supof cyclophosphamide alone (n = 2), cyclophosphamide, etoported by PBSC. The second protocol was a randomized poside (CE) and filgrastim (n = 48) or cyclophosphamide, phase III trial of cyclophosphamide, etoposide (CE) vs etoposide, cisplatin (CEP) and filgrastim (n = 28), etoposide cyclophosphamide, etoposide, cisplatin (CEP) for mobilizand filgrastim (n = 1) or CEP and granulocyte-macrophage ation of PBSC prior to the administration of BEAC.
colony-stimulating factor (n = 4), as previously Patients were required to have an ECOG performance described. 28, 32 status of 0-2, be age 66 or less, and have evidence of The goal was to collect у2.5 × 10 6 CD34 + cells/kg. Eight adequate hepatic, renal and cardiac function. All patients patients who achieved less than this target dose underwent a signed informed consent approved by the institutional second mobilization procedure with cyclophosphamide and review board of the hospital where the therapy was adminfilgrastim (n = 2), CE and filgrastim (n = 4) or CEP and istered.
filgrastim (n = 2). 28, 32 One patient had bone marrow harvested to augment a CD34 + cell dose in the PBSC product of 0.64 × 10 6 /kg. Definitions
Patients were classified according to the Working formu-
Collection and cryopreservation of PBSC lation. 29 Primary induction failure was defined as failure to achieve an initial CR following a full course of combination Peripheral blood stem cells were collected and cryoprechemotherapy with cyclophosphamide, doxorubicin, vincriserved as previously described. 28, 32 Cryopreserved PBSC stine and prednisone (CHOP), methotrexate with leucovowere thawed and infused 72 h after the last dose of chemorin rescue, doxorubicin, cyclophosphamide, vincristine, therapy. The day of PBSC infusion was designated day 0. prednisone and bleomycin (MACOP-B) or prednisone, doxorubicin, cyclophosphamide, and etoposide followed by cytarabine, bleomycin, vincristine and methotrexate with High-dose chemotherapy (BEAC) leucovorin rescue (ProMACE-CytaBOM). 30 Complete remission was defined as total resolution of measurable Carmustine 300 mg/m 2 was administered on day −7, etoporadiographic or clinical disease. Partial remission (PR) was side 150 mg/m 2 /i.v. twice a day on days −6, −5, −4 and −3, defined as a greater than 50% reduction in the product of cytarabine 100 mg/m 2 /i.v. twice a day on days −6, −5, −4 the perpendicular diameter of measurable disease. Sensitive and −3, and cyclophosphamide 35 mg/kg/day/i.v. on days disease was defined as уPR to reinduction chemotherapy. −6, −5, −4 and −3.
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Patients who were induction failures or in untreated relapse-1 were not categorized for chemotherapy sensitivity. Staging was performed prior to mobilization of Supportive care PBSC and 4-6 weeks after HDC.
Prior radiotherapy was defined as radiotherapy adminisPatients received HDC in a specially designed outpatient tered to any site at any dose before the administration of treatment facility with daily surveillance for complications mobilization chemotherapy. Mediastinal irradiation was warranting hospital admission such as febrile neutropenia defined as у2000 cGy.
or inadequate oral intake. Patients who were serologically Neutrophil engraftment was defined as the first of 3 conpositive for herpes simplex virus, received prophylactic secutive days on which the absolute neutrophil count acyclovir. Fluconazole 200 mg orally daily was adminis-(ANC) was у0.5 × 10 9 /l following the nadir. Platelet tered from the start of chemotherapy until neutrophil recovengraftment was defined as the first of 7 consecutive days ery. Chemoprophylaxis was not given for Pneumocystitis on which the platelet count exceeded 20.0 × 10 9 /l unsupcarinii pneumonia. Patients who were sero-negative for ported by transfusions.
cytomegalovirus (CMV) received antibody screened or filtered blood products. Patients seropositive for CMV did not receive chemoprophylaxis with antiviral agents. Following Treatment centers the administration of HDC, prophylactic systemic antibiotics were administered during neutropenia. Patients were treated in one of 21 participating community medical centers in the United States under the care of 46 Seventy-five of 83 patients (90%) received filgrastim 6 g/kg/s.c./day or leukine 250 mg/m 2 /day starting on day community oncologists. 28 Chemotherapy was administered and PBSC harvested in an outpatient facility by nurses and 1 until the ANC count was у0.5 × 10 9 /l for 3 consecutive days and eight received no growth factor after infusion medical technicians. Initially, at the completion of PBSC infusions, patients were admitted to hospitals meeting the of PBSC.
755 Table 1 Patient characteristics (n = 83)
Toxicity grading
All patients were evaluated daily until resolution of signs
No. (%)
and symptoms and graded for toxicity using standard criteria. 33 Interstitial pneumonia syndrome (IPS) was defined (33) tious cause. 34 Veno-occlusive disease (VOD) of the liver CR-2 or treated relapse-1 18 (21) was defined as liver toxicity secondary to chemotherapy, Sensitive 10 and the diagnosis was made on the basis of hepatomegaly Resistant 8 and/or liver tenderness, weight gain Ͼ2% of baseline and venules, dilatation of the sinusoids and necrosis of hepatoPrior radiotherapy 22 (27) cytes. Weaver) for consistency.
High grade 18 (22) Probabilities of relapse/progression, survival (OS) and Immunoblastic 10 EFS were estimated using the product-limit method accordSmall non-cleaved cell 5
ing to Kaplan and Meier. 36 Univariate comparisons of the Lymphoblastic 3 Transformed from lower grade 8 (9) different prognostic variables were evaluated using the log- clinical or pathological evidence of progression of disease,
Gender -female 33 (40) or of relapse if patients were in CR. The endpoint for EFS
Median age, years (range) 48 (23-66) was progression/relapse or death without progression/ relapse censored for date of last contact with the date of last follow-up being 1 April 1997. All proportions were Adminstration of mobilizing chemotherapy and collection compared using 2 of Fisher's exact test as appropriate. of PBSC Thirty-three patients (39%) were hospitalized a median of Results 6 days (range 3-25) following the administration of mobilizing chemotherapy.
Patient characteristics
A median of 13.1 × 10 6 CD34 + cells/kg (range 0.03-84.5) was collected with a median of 3 (range 1-6) apherPatient characteristics are listed in Table 1 . Twenty-eight patients were primary induction failures after one (n = 25) eses. Eight patients failing to achieve у2.5 × 10 6 /kg CD34 + cells underwent a second mobilization procedure where a or Ͼ1 treatment regimens (n = 3). Twenty-seven patients were treated in first relapse without attempts at reinduction. median of 1.5 × 10 6 CD34 + cells/kg (range 0.08-4.4) were collected in a median of 5 (range 4-6) aphereses. When Eighteen patients received chemotherapy at first relapse and eight achieved a PR and two a CR while eight achieved second harvests were added to first harvests, the median number of CD34 + cells collected was 13.3 × 10 6 /kg (range less than a PR and were classified as resistant. Four patients in second or subsequent relapse did not receive treatment 0.64-84.5). before chemotherapy for mobilization while six patients received chemotherapy for second or greater relapse and High-dose chemotherapy two achieved a PR or CR and four achieved less than a PR and were classified as resistant. Thus, 12 patients had Protocol compliance: All 83 patients received all the prescribed drug doses. demonstrably chemotherapy sensitive and 12 had resistant disease.
Twenty-two patients had received prior radiation therapy Hospitalization: Eighty patients (96%) were hospitalized a median of 14 days (range 6-37) while three patients comand six of these had received у2000 cGy to the mediastinum.
pleted therapy totally in an outpatient setting.
Engraftment: A median of 9.7 × 10 6 CD34 + cells/kg (range row involvement vs no marrow involvement or male vs female. 2.4-84.5) were infused into 82 patients while one received bone marrow (3.0 × 10 8 total nucleated cells/kg) and PBSC Multivariate analyses were not performed due to failure to identify any factors significantly associated with out-(0.64 × 10 6 CD34 + cells/kg). Two patients died on days 1 and 50 before neutrophil come in univariate analyses. recovery. The median time to achieve an ANC у0.5 × 10 9 /l for the 81 evaluable patients was 10 days (range 8-32).
Four of 83 patients died on days 1, 12, 36 and 50 before Discussion platelet recovery. The median time to achieve platelets у20.0 × 10 9 /l for 79 evaluable patients was 10 days (range These data confirm that unmanipulated autologous PBSC result in rapid and complete engraftment in the majority of 6-35). The patient who died on day 50, of VOD of the liver, without neutrophil or platelet recovery had received patients with NHL receiving HDC. Six patients (7.2%) died of treatment-related complications but only one died from 11.1 × 10 6 CD34 + cells/kg. Patients required a median of four platelet (range 0-18) bacterial infection and there were no deaths from fungal infection. The average hospitalization time was 14 days and two red blood cell transfusions (range 0-15).
with three patients not requiring admission. Two of 11 patients (18%) with a performance status greater than 1 Transplant-related mortality: Six of 83 patients (7.2%) died from causes other than relapse within 100 days of died of treatment-related causes as compared to 4/72 patients (5.5%) with a performance status of 0 (P = 0.18). PBPC infusion. Four patients (4.8%) died of regimenrelated toxicity: two from IPS on days 17 and 36, one from Although the numbers are small this observation would be consistent with those of others who have found that poor an atrial arrhythmia on day 1 and one from VOD of the liver on day 50. There were two deaths from infection performance status predicted for an adverse outcome following autologous marrow transplantation for patients with (2.4%): one from Staphylococcus aureus septicemia on day 12 and one from probable viral hepatitis on day 81. malignant lymphoma. 17 Thus, the relatively low transplantrelated mortality in the current study may reflect the selecOne of six patients with a history of mediastinal radiation died of IPS as compared to 1/77 patients not receiving tion of patients (82%) with a good performance status. These data document that a well-tested HDC regimen, mediastinal radiation therapy.
There have been two late deaths unrelated to relapse: one such as BEAC, followed by PBSC infusion can be administered with relative safety by practicing oncologists in comfrom cardiac failure on day 574 in a patient who had received mediastinal radiation and one from an automobile munity cancer centers with a treatment-related mortality similar to that reported from large single institution 14 or accident on day 927. multi-institutional trials. 1 More importantly, these data demonstrate that meaningful clinical trials of HDC and Relapse/progression (Table 2 and Figures 1 and 2 ): The probability of relapse/progression at 3 years for the entire PBSC infusions could be carried out by practicing oncologists in community cancer centers. However, such studies 83 patients was 0.57. The probabilities of relapse/ progression at 3 years for various subsets of patients ranged should involve well-tested HDC regimens and patients with a good performance status. from 0.40 to 0.77 but none of the differences between subgroups reached statistical significance ( Table 2) .
The current study was carried out using unpurged PBSC. Methodologies for marrow purging have been utilized for more than a decade. [37] [38] [39] [40] [41] [42] [43] However, there have been no ranSurvival and event-free survival (Table 2 and Figures 1-3 ): The probabilities of OS and EFS at 3 years for the domized controlled trials evaluating survival or relapse following the infusion of purged vs unpurged marrow in entire group were 0.49 and 0.38, respectively (Figure 1) . The probabilities of survival and EFS at 3 years for the 28 patients with NHL. A case-matched comparison of purged with unpurged marrow infusion in patients with NHL has patients who were primary induction failures were 0.42, and 0.38 ( Figure 2 ). The probabilities of survival and EFS been carried out by the European Blood and Marrow Transplant Registry. 44 In patients with intermediate-grade, lymat 3 years for the 27 patients receiving mobilization chemotherapy and HDC without an attempt at reinduction were phoblastic and other high-grade histologies, there were no differences in survival between purged and unpurged 0.52 and 0.44 ( Figure 3) . The probabilities of survival and EFS at 3 years for the 18 patients who were treated for first groups. 44 Peripheral blood stem cells have been purged in patients with NHL by density gradient separation followed relapse before mobilization chemotherapy were 0.56 and 0.32 (P = 0.81 and 0.99) (Figure 3) .
by monoclonal antibody incubation 45 and in patients with multiple myeloma by positive selection of CD34 + cells. 46 However, there is no documentation that current purging Univariate analyses: Table 2 shows the results of univariate analyses on outcome. There were no significant differtechniques for PBSC decrease relapses in patients with NHL. ences in OS, relapse/progression, TRM or EFS between the following groups: primary induction failures vs all others, Mediastinal radiation has been identified as an adverse risk factor for the development of IPS following high-dose untreated relapse-1 vs treated relapse-1, sensitive relapse vs resistant relapse, prior radiotherapy vs no prior radiochemo-radiotherapy and regimens containing high doses of carmustine. 3, 47, 48 Only six patients in the current study had therapy, prior chemotherapy regimens = 1 vs Ͼ1, intermediate-grade histology vs high-grade vs transformed, B received mediastinal radiation and one (17%) developed fatal IPS following HDC. One patient who had received symptoms vs no B symptoms, age Ͼ56 vs р56 years, mar- a Probability at 3 years using product-limit method. Relapse = probability of relapse or progression; OS = probability of overall survival; TRM = treatment-related mortality; EFS = probability of eventfree survival. Univariate analyses between above groups produced no P values Ͻ0.18. and relapse/progression (----) for 28 patients who had failed primary induction.
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mediastinal radiation died of cardiac failure 574 days after HDC, two are alive with progressive disease and two are effective conditioning regimen for patients with intermediate and high-grade NHL who have failed conventional alive disease-free. These data are too limited to determine the effectiveness of BEAC as compared to other regimens chemotherapy with outcomes comparable to other HDC or chemo-radiotherapy regimens. 2, 4, 8, [10] [11] [12] [13] [14] [15] [16] [17] [18] [20] [21] [22] However, this for patients with a history of mediastinal radiation.
High-dose chemotherapy with BEAC resulted in an EFS does not mean that BEAC is an optimal regimen for patients with NHL who fail chemotherapy. It remains to be at 3 years of 38%. These data confirm that BEAC is an of Wheeler et al, 14 all eight patients with small non-cleaved or lymphoblastic histology failed HDC with carmustine, etoposide and cyclophosphamide. In the current study there were 15 patients with the same histology and five (33%) are alive disease-free. Larger patient populations will have to be evaluated to determine the effect of histology on outcome of HDC and PBSC infusion.
In conclusion, mobilization of PBPC with CE or CEP followed by high-dose BEAC is an effective strategy for the treatment of patients with NHL who have relapsed after chemotherapy. This therapy is associated with low mortality and morbidity when administered in community hospitals with appropriate supportive care and adequate numbers of PBPC. Current and future studies being carried out and to determine the optimal timing of intervention with mobilization chemotherapy and high-dose chemotherapy without attempts at induction chemotherapy (--) and for 18 patients who were treated HDC and PBSC rescue.
with mobilization chemotherapy and high-dose chemotherapy after induction chemotherapy ($$$).
Acknowledgements determined if regimens containing total body irradiation or regimens that are more intensive are more effective.
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The following physicians participated in this study: R Giudice Currently, we are investigating a more intensive regimen However, 12 patients were known to be resistant to chemotherapy prior to mobilization chemotherapy and they had an EFS of 25% as compared to 38% for 12 patients with References chemo-sensitive disease (P = 0.48). These numbers are obviously too small for meaningful comparison. tion, had a 44% EFS at 3 years which was no different than lymphoma. New Engl J Med 1995; 333: 1540-1545.
for patients who had attempts at reinduction (Figure 3) . In the current study, histology was not predictive of out-5 Goldstone AH, Singer CRJ, Gribben JG, Jarrett M, Group come but the probability of relapse at 3 years was highest 75%, respectively. Although the numbers were small 6/8 33-36. 6 Brunvand MW, Appelbaum FR, Soll E et al. High-dose fracpatients with transformed histology relapsed. In the study
